Every staff member and provider has been so warm, patient, and genuinely helpful they make me feel like I matter
Promotes skin clarity and overall glow
*Frequency individualized based on physician assessment
The most common adverse effects are gastrointestinal in nature, affecting up to 4050% of patients, particularly during treatment initiation or dose escalation
While both can help with weight and blood sugar, they work in fundamentally different ways
Results Enrollment and baseline demographics Herein we report results of a phase 1 clinical trial (www.clinicaltrials.gov, NCT02943239), involving a randomized, double-blind, placebo-controlled comparison assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the GDF8 mAb, trevogrumab, and the ActA mAb, garetosmab, each given alone, as well as the GDF8 mAb given in combination with increasing dose levels of the ActA mAb